Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01953107|
Recruitment Status : Recruiting
First Posted : September 30, 2013
Last Update Posted : April 25, 2017
The prevalence of anemia in gynecologic oncology new patients has been seen in previous studies to be as high as 35-59%. this population includes women with several types of gynecologic malignancies. Therefore, it is assumed that the origin of the anemia can be due to anemia of chronic disease and iron deficiency anemia. No previous studies have looked at the efficacy of oral iron supplementation with concurrent Vitamin C in women with newly diagnosed gynecologic malignancies.
Hypothesis: In newly diagnosed gynecologic oncology patients who are surgical candidates does treatment with 3-6 weeks of oral ferrous fumarate 300 mg once a day improve the mean change in hemoglobin levels, from baseline to pre-operative, in comparison to placebo.
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer Cervical Cancer Uterine Cancer Anemia||Other: Oral Ferrous Fumarate Other: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates.|
|Study Start Date :||November 2013|
|Actual Primary Completion Date :||January 2017|
|Estimated Study Completion Date :||November 2017|
Experimental: Ferrous Fumarate 300 mg + Vitamin C
300 mg once a day of Oral Ferrous Fumarate
|Other: Oral Ferrous Fumarate|
Placebo Comparator: Placebo + Vitamin C
300 mg of Placebo
- Mean Difference in Hemoglobin [ Time Frame: Pre-surgery (4-6 weeks) ]The mean difference in the change of hemoglobin levels from baseline to the day of surgery between participants treated with oral iron versus. placebo.
- Quality of life [ Time Frame: Baseline to Pre-surgery (4-6 weeks) ]The difference in quality of life (FACT-An) between patients treated with ferrous fumarate 300 mg. daily to placebo.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01953107
|Contact: Amanda Fonseca, Clinical Research Associate||416-480-5000 ext email@example.com|
|Odette Cancer Centre||Recruiting|
|Toronto, Ontario, Canada, M4N 3M5|
|Principal Investigator: Dr. Danielle Vicus, MD|
|Principal Investigator:||Danielle Vicus, MD||Odette Cancer Centre|